25 min listen
Moving to an Allogeneic RNA Cell Therapy Program with Cartesian Therapeutics' Dr. Metin Kurtoglu
Moving to an Allogeneic RNA Cell Therapy Program with Cartesian Therapeutics' Dr. Metin Kurtoglu
ratings:
Length:
20 minutes
Released:
May 26, 2022
Format:
Podcast episode
Description
Dr. Metin Kurtoglu, COO at Cartesian Therapeutics, explains the clinical-stage biotech's autologous RNA cell therapies, Descartes-08 for Myasthenia Gravis and Descartes-11 for multiple myeloma. He also explains Descartes-25, their allogeneic RNA cell therapy and the reasons for the move to "off-the-shelf," and why the future of RNA cell therapy is not confined to rare and fatal diseases. We also discuss post-care for patients having received infusions.
Released:
May 26, 2022
Format:
Podcast episode
Titles in the series (76)
Advancing Patient Engagement with Novartis Gene Therapies' Dr. Amy Nicole Nayar by Cell & Gene: The Podcast